Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines

@article{Collins2009TyrosineKI,
  title={Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines},
  author={Denis M. Collins and John Crown and Norma O’Donovan and Aoife Devery and Finbarr O’Sullivan and Lorraine O’Driscoll and Martin M. Clynes and Robert M. O’Connor},
  journal={Investigational New Drugs},
  year={2009},
  volume={28},
  pages={433-444}
}
To investigate the interactions of Epidermal Growth Factor Receptor (EGFR)-inhibiting tyrosine kinase inhibitors (TKIs) on P-gp-mediated drug resistance, we tested three TKIs, lapatinib, gefitinib and erlotinib in direct ATPase assays and in Non-Small Cell Lung Cancer (NCSLC) cell lines with defined low levels of growth factor receptor expression. The three TKIs potentiated the action of known P-gp substrate cytotoxic drugs at therapeutically-relevant concentrations. However, more detailed… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 35 references

A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer

  • R O'Connor
  • Cancer Chemother Pharmacol
  • 2007
1 Excerpt

Signal transduction therapy with rationally designed kinase inhibitors

  • G Keri, L Orfi
  • Curr Signal Transduct Ther 1:67–95
  • 2006
1 Excerpt

Similar Papers

Loading similar papers…